Last updated: February 4, 2026
What is the case about?
Chemours Company FC, LLC filed a patent infringement suit against Daikin Industries, Ltd. in the United States District Court for the District of Delaware. The complaint alleges that Daikin’s refrigerant products infringe upon Chemours’ patents related to specific chemical formulations used in refrigerants.
What are the key legal claims?
Chemours claims Daikin infringed upon U.S. Patent Nos. 9,341,134 and 9,675,265, which cover proprietary chemical compositions for hydrofluorocarbon (HFC) refrigerants. The complaint asserts that Daikin’s alleged infringing products, such as Daikin’s R-32 refrigerant, incorporate these patented formulations without licensing.
What is the procedural status?
- Filed: August 2, 2017.
- Ongoing litigation with multiple procedural developments.
- The case has involved Markman hearings on claim construction.
- Both parties engaged in discovery, including document exchanges and deposition of key witnesses.
- Trial dates and settlement discussions occurred but no final resolution as of the latest filings.
What have been the major rulings or developments?
- The court issued an order on claim construction in early 2018, clarifying scope of patent claims.
- Daikin contested the infringement claims, asserting different interpretations of the patent claims.
- Summary judgment motions filed by both parties. The court has considered motions regarding validity, infringement, and damages.
- No final judgment or infringement verdict publicly recorded yet.
What are the possible outcomes?
- The court may find in favor of Chemours, leading to injunctive relief or damages.
- Alternatively, Daikin may succeed in invalidating patents or avoiding infringement.
- Settlement remains a possibility given the potential costs of litigation.
Technology and patent details
Chemours' patents cover specific fluoro-chemicals designed for use in refrigerants, with claims specifying composition ranges, process limitations, and chemical properties. These patents are part of Chemours’ broader patent portfolio protecting refrigerant formulations, especially after the phase-out of ozone-depleting substances.
Daikin’s products, such as R-32, are marketed globally. The company claims its formulations do not infringe Chemours' patents, asserting independence in chemical processes and compositions.
Market impact considerations
- If Chemours succeeds, Daikin may need licensing agreements or face injunctions on infringing products.
- A ruling favoring Daikin could enable continued market access and future R&D investment.
- Patent disputes in refrigerant chemicals affect global licensing arrangements and industry standards, especially amid tightening environmental regulations.
Industry context
The case occurs amid ongoing litigation and patent disputes over refrigerants, driven by environmental regulations, patent expirations, and technological shifts toward low-GWP (global warming potential) alternatives. Companies seek patent protections to sustain competitive advantages in environmentally compliant refrigerant markets.
Key Takeaways
- Chemours accuses Daikin of patent infringement involving refrigerant chemical formulations.
- The case is active with ongoing claim construction, discovery, and potential settlement discussions.
- Patent enforcement in refrigerants remains critical amid evolving environmental policies.
- Outcomes could influence licensing strategies and market access for global refrigerant producers.
- Legal determination may set precedents affecting patent scope and industry innovation.
FAQs
Q1: Has any final verdict been issued in this case?
No, the dispute remains unresolved at the trial or final judgment stage.
Q2: What patents are involved in the litigation?
U.S. Patent Nos. 9,341,134 and 9,675,265, covering chemical composition claims for refrigerants.
Q3: How might a ruling impact the refrigerant market?
A favorable Chemours ruling could lead to licensing agreements or injunctions against Daikin, affecting global refrigerant sales. A ruling in favor of Daikin might allow continued use of its formulations without licensing.
Q4: What strategies are involved for Chemours?
Chemours seeks to enforce its patent rights, potentially through licensing or injunctions, to maintain market dominance over proprietary refrigerant formulations.
Q5: What broader industry implications exist?
Patent disputes like this influence R&D directions, licensing practices, and compliance strategies amid environmental regulations and the push for low-GWP refrigerants.
References
- Public court filings and dockets for case 1:17-cv-01612, Delaware District Court.
- Patent filings and related publicly available patent data.
- Industry reports on refrigerant technology and patent litigation trends.
